Secondary Logo

Journal Logo

Erratum

A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol: Erratum

doi: 10.1097/GME.0000000000000728
  • Free

In the article appearing in volume 23, pages 506-510, of Menopause, entitled “A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol,” there was an error.

On page 506, several conflict of interest disclosures were not published for the article.

In the case of author Brian A. Bernick, MD, disclosures were made prior to the article's publication but, inadvertently, were not published with the final article. They are:

Dr Bernick is an employee/board member of TherapeuticsMD and has stock and options with TherapeuticsMD.

The following authors did not fully disclose conflicts of interest as required by the journal and would like to make the following disclosures:

The authors Julia M. Amadio and Sebastian Mirkin, MD are employed by TherapeuticsMD as noted in the published article, and they also disclose that they own stock options in the company.

The authors regret their oversight.

REFERENCE

1. Pickar JH, Amadio JM, Hill JM, Bernick BA, Mirkin S. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol. Menopause 2016; 23:506–510.
    © 2016 by The North American Menopause Society